EUR 3.92
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 6.35 Million EUR | 21362.89% |
2022 | 536.79 Thousand EUR | 103.51% |
2021 | 523 Thousand EUR | -5.06% |
2020 | 881.42 Thousand EUR | -520.04% |
2019 | 605.13 Thousand EUR | -57.59% |
2018 | -1.12 Million EUR | 30.68% |
2017 | 186.69 Thousand EUR | 6.01% |
2016 | 1.01 Million EUR | 6.45% |
2015 | 1.12 Million EUR | -7.05% |
2014 | 1.19 Million EUR | 31.09% |
2013 | 794.04 Thousand EUR | 75.65% |
2012 | 452.05 Thousand EUR | -55.54% |
2011 | 800.4 Thousand EUR | -19.16% |
2010 | 1.25 Million EUR | 65.59% |
2009 | 759.54 Thousand EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 881 Thousand EUR | 0.0% |
2023 FY | - EUR | 21362.89% |
2023 Q2 | 338.66 Thousand EUR | 0.0% |
2023 Q4 | 10.76 Million EUR | 0.0% |
2022 FY | - EUR | 103.51% |
2022 Q4 | 538.96 Thousand EUR | 0.0% |
2022 Q2 | -445.3 Thousand EUR | 0.0% |
2021 Q4 | -1.03 Million EUR | 0.0% |
2021 FY | - EUR | -5.06% |
2021 Q2 | -1.63 Million EUR | 0.0% |
2020 Q2 | -1.88 Million EUR | 0.0% |
2020 Q4 | -659.01 Thousand EUR | 0.0% |
2020 FY | - EUR | -520.04% |
2019 Q2 | -378 Thousand EUR | 0.0% |
2019 Q4 | -1.03 Million EUR | 0.0% |
2019 FY | - EUR | -57.59% |
2018 Q2 | 785.2 Thousand EUR | 0.0% |
2018 FY | - EUR | 30.68% |
2018 Q4 | 641.62 Thousand EUR | 0.0% |
2017 Q2 | 500.65 Thousand EUR | 0.0% |
2017 FY | - EUR | 6.01% |
2017 Q4 | 548.15 Thousand EUR | 0.0% |
2016 Q4 | 680.27 Thousand EUR | 0.0% |
2016 Q2 | 349.68 Thousand EUR | 0.0% |
2016 FY | - EUR | 6.45% |
2015 Q2 | 521.04 Thousand EUR | 0.0% |
2015 Q4 | 446.53 Thousand EUR | 0.0% |
2015 FY | - EUR | -7.05% |
2014 Q4 | 682.88 Thousand EUR | 0.0% |
2014 FY | - EUR | 31.09% |
2014 Q2 | 358.05 Thousand EUR | 0.0% |
2013 Q2 | 234.5 Thousand EUR | 0.0% |
2013 Q4 | 559.54 Thousand EUR | 0.0% |
2013 FY | - EUR | 75.65% |
2012 Q3 | 64.63 Thousand EUR | 0.0% |
2012 Q1 | 64.63 Thousand EUR | 0.0% |
2012 Q4 | 215.44 Thousand EUR | 233.31% |
2012 FY | - EUR | -55.54% |
2012 Q2 | 64.63 Thousand EUR | 0.0% |
2011 Q3 | 210.41 Thousand EUR | 0.0% |
2011 FY | - EUR | -19.16% |
2011 Q4 | 64.63 Thousand EUR | -69.28% |
2011 Q2 | 210.41 Thousand EUR | 0.0% |
2011 Q1 | 210.41 Thousand EUR | 0.0% |
2010 Q1 | 299.8 Thousand EUR | 0.0% |
2010 Q4 | 210.41 Thousand EUR | -29.82% |
2010 FY | - EUR | 65.59% |
2010 Q3 | 299.8 Thousand EUR | 0.0% |
2010 Q2 | 299.8 Thousand EUR | 0.0% |
2009 FY | - EUR | 0.0% |
2009 Q1 | 138.9 Thousand EUR | 0.0% |
2009 Q4 | 299.8 Thousand EUR | 115.84% |
2009 Q3 | 138.9 Thousand EUR | 0.0% |
2009 Q2 | 138.9 Thousand EUR | 0.0% |
2008 Q4 | 138.9 Thousand EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
ABIONYX Pharma SA | -3.29 Million EUR | 293.032% |
ABIVAX Société Anonyme | -133.2 Million EUR | 104.768% |
Adocia SA | -22.73 Million EUR | 127.937% |
Aelis Farma SA | -6.34 Million EUR | 200.059% |
Biophytis S.A. | -13.8 Million EUR | 146.007% |
Advicenne S.A. | -6.24 Million EUR | 201.71% |
IntegraGen SA | -52.5 Thousand EUR | 12195.975% |
Medesis Pharma S.A. | -3.84 Million EUR | 265.174% |
Neovacs S.A. | -8.44 Million EUR | 175.161% |
NFL Biosciences SA | -4.04 Million EUR | 256.836% |
Plant Advanced Technologies SA | 72.53 Thousand EUR | -8656.032% |
Quantum Genomics Société Anonyme | -2.87 Million EUR | 321.013% |
Sensorion SA | -22.31 Million EUR | 128.461% |
Theranexus Société Anonyme | -7.38 Million EUR | 185.969% |
TME Pharma N.V. | -5.07 Million EUR | 225.212% |
Valbiotis SA | -6.95 Million EUR | 191.312% |
TheraVet SA | -517.33 Thousand EUR | 1327.587% |
Valerio Therapeutics Société anonyme | -18.91 Million EUR | 133.573% |
argenx SE | -199.5 Million EUR | 103.183% |
BioSenic S.A. | -6.79 Million EUR | 193.448% |
Celyad Oncology SA | -7.76 Million EUR | 181.808% |
DBV Technologies S.A. | -79.53 Million EUR | 107.985% |
Galapagos NV | 51.03 Million EUR | 87.557% |
Genfit S.A. | -28.05 Million EUR | 122.64% |
GeNeuro SA | -14.31 Million EUR | 144.356% |
Hyloris Pharmaceuticals SA | -14.98 Million EUR | 142.395% |
Innate Pharma S.A. | -7.57 Million EUR | 183.805% |
Inventiva S.A. | -101.84 Million EUR | 106.236% |
MaaT Pharma SA | -19.74 Million EUR | 132.172% |
MedinCell S.A. | -20.04 Million EUR | 131.681% |
Nanobiotix S.A. | -34.01 Million EUR | 118.668% |
Onward Medical N.V. | -35.23 Million EUR | 118.024% |
Oryzon Genomics S.A. | -4.43 Million EUR | 243.249% |
OSE Immunotherapeutics SA | -23.26 Million EUR | 127.296% |
Oxurion NV | -16.72 Million EUR | 137.963% |
Pharming Group N.V. | 4.98 Million EUR | -27.5% |
Poxel S.A. | -12.17 Million EUR | 152.145% |
GenSight Biologics S.A. | -21.73 Million EUR | 129.226% |
Transgene SA | -27.02 Million EUR | 123.5% |
Financière de Tubize SA | 184.57 Thousand EUR | -3340.817% |
UCB SA | 1.26 Billion EUR | 99.5% |
Valneva SE | -64.51 Million EUR | 109.844% |
Vivoryon Therapeutics N.V. | -28.35 Million EUR | 122.399% |